NCT04590547: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) |
|
|
| Active, not recruiting | 2 | 132 | Europe, US, RoW | GLS-1027, Placebo | GeneOne Life Science, Inc. | Pneumonitis, SARS-CoV Infection | 08/22 | 12/23 | | |
2021-002730-16: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Sever Pneumonitis caused by COVID-19 |
|
|
| Not yet recruiting | 2 | 200 | Europe | GLS-1027, GLS-1027, Capsule | GeneOne Life Science Inc., GeneOne Life Science Inc. | Patients with SARS-CoV-2 infection, Patients with COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
